射血分数保留的心力衰竭的诊断和治疗策略(4)
5 小结
HFpEF约占心衰总数的50%,其发病率及致死率有逐年上升的趋势。目前还面临着许多问题和挑战:HFpEF的发病机制尚不明确、既往缺乏统一的诊断标准、患者合并症较多、缺乏有效的治疗方法、大量临床试验呈阴性结果等,这些问题需要进一步完善和丰富基础、临床研究,寻找更多的证据,为HFpEF患者提供治疗的依据,以改善其生活质量,降低心血管事件的发生率和病死率。
作者贡献:刘蔚负责文章的构思与设计,论文修订,文章的质量控制及审校,并对文章整体负责、监督管理;尉然负责检索文献、撰写论文。
本文无利益冲突。
[1]LAM C S,DONAL E,KRAIGHER-KRAINER E,et al.Epidemiology and clinical course of heart failure with preserved ejection fraction[J].Eur J Heart Fail,2011,13(1):18-28.DOI:10.1093/eurjhf/hfq121.
[2]OWAN T E,REDFIELD M of diastolic heart failure[J].Prog Cardiovasc Dis,2005,47(5):320-332.DOI:10.1016/
[3]LIU D P,WANG F,ZENG X Z,et al.Clinical characteristics and prognosis of heart failure with normal left ventricular ejection fraction in elderly patients[J].Chin Med J(Engl),2012,125(16):2853-2857.
[4]张健,张宇辉,代表中国心力衰竭注册登记协作组.多中心、前瞻性中国心力衰竭注册登记研究——病因、临床热点和治疗情况初步分析[J].中国循环杂志,2015,30(5):413-416.
[5]MAGGIONI A P,DAHLSTR?M U,FILIPPATOS G,et al.EURObservational research programme:regional differences and 1-year follow-up results of the heart failure pilot survey(ESC-HF pilot)[J].Eur J Heart Fail,2013,15(7):808-817.DOI:10.1093/eurjhf/hft050.
[6]OWAN T E,HODGE D O,HERGES R M,et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med,2006,355(3):251-259.DOI:10.1056/nejmoa0.
[7]LEE D S,GONA P,VASAN R S,et al.Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction:insights from the Framingham heart study of the national heart,lung,and blood institute[J].Circulation,2009,119(24):3070-3077.DOI:10.1161/CIRCULATIONA HA.108..
[8]SANTHANAKRISHNAN R,CHONG J P,NG T P,et al.Growth differentiation factor 15,ST2,high-sensitivity troponin T,and N-terminal pro brain natriuretic peptide in heart failure with preserved ejection fraction[J].Eur J Heart Fail,2012,14(12):1338-1347.DOI:10.1093/eurjhf/hfs130.
[9]CHENG J M,AKKERHUIS K M,BATTES L C,et al.Biomarkers of heart failure with normal ejection fraction:a systematic review[J].Eur J Heart Fail,2013,15(12):1350-1362.DOI:10.1093/eurjhf/hft106.
[10]SANDERS-VAN WIJK S,VAN EMPEL V,DAVARZANI N,et al.Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved left ventricular ejection fraction[J].Eur J Heart Fail,2015,17(10):1006-1014.DOI:10.1002/
[11]D'ELIA E,VADUGANATHAN M,GORI M,et al.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction:critical appraisal and practical use[J].Eur J Heart Fail,2015,17(12):1231-1239.DOI:10.1002/
[12]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[13]PONIKOWSKI P,VOORS A A,ANKER S D,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.DOI:10.1002/
[14]ANDERSON J L,HALPERIN J L,ALBERT N M,et al.Management of patients with atrial fibrillation(compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations):a report of the American College of Cardiology/American Heart Association Task force on practice guidelines[J].J Am Coll Cardiol,2013,61(18):1935-1944.DOI:10.1016/
[15]YANCY C W,JESSUP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America[J].Circulation,2017,136(6):e137-161.DOI:10.1161/
[16]CUNNINGHAM J W,VADUGANATHAN M,CLAGGETT B L,et al.Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction[J].JACC:Heart Fail,2020,8(5):372-381.DOI:10.1016/
文章来源:《诊断病理学杂志》 网址: http://www.zdblxzz.cn/qikandaodu/2021/0226/395.html